Jade Biosciences, Inc. (JBIO)
NCM · Healthcare · Biotechnology
$17.89
-6.53%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.14B
Shares Outstanding
63.6M
Exchange
NCM
Currency
USD
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (27.4M) | (35.0M) | (43.4M) | (58.9M) |
| Net Income | (25.2M) | (31.9M) | (40.4M) | (55.8M) |
| Diluted EPS | $-0.48 | N/A | $-0.57 | $-0.76 |
Annual Financials
| Metric | 2025-12-31 |
|---|---|
| Revenue | 0.00 |
| Operating Income | (113.5M) |
| Net Income | (127.4M) |
| Diluted EPS | $-3.19 |